EGFR and non-small cell lung carcinoma: Although postoperative TKI therapy has been reported to extend PFS after surgery in patients with completely resected EGFR-mutant NSCLC [22–24], there is little literature on the effectiveness of postoperative TKI therapy for patients undergoing salvage surgery for NSCLC.